NCT05703516
A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea
StatusActive, Not Recruiting
PhaseNot specified
SponsorNovartis Pharmaceuticals
Primary completion (estimated)
At risk: Primary completion moved 30 days later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 9 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 6 words Show 4 more changesShow less
- Enrollment closed, study ongoing
- Primary and study completion pushed from Oct 31, 2026 to Nov 30, 2026
- Final enrollment: 20 participants (planned 44)
- Site details revised at 10 of 10 sites
- Notable Enrollment target: 250 to 44
- Study sites: 12 to 10
- Notable Primary and study completion dates: Oct 31, 2024 to Oct 31, 2026
- Site details revised at 1 of 12 sites
- Minor Study sites: 8 to 12v6
- Minor Study sites: 7 to 8v5
Show 3 earlier versionsHide 3 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 7
- Start date changed from estimate of Jun 30, 2023 to Jun 12, 2023
- Notable Start date: May 31, 2023 to Jun 30, 2023
- Primary and study completion dates moved earlier to Oct 31, 2024
- Notable Start date: Feb 13, 2023 to May 31, 2023v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of participants with adverse events (AEs) and serious adverse events (SAEs).
Timeframe: From date of first study dose to end of study, assessed up to approximately 28 weeks
Secondary (2)
Objective response rates (ORRs) assessed by investigator
Progression Free Survival (PFS)
Arms and interventions
Capmatinib
Participants will be treated with capmatinib as per locally approved label
Other: Capmatinib
Sites
10 sites in 1 country